NCT06266988: A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions |
|
|
| Not yet recruiting | 1 | 48 | NA | Sacubitril and Valsartan Tablets 97mg/103mg, Sacubitril and Valsartan Tablets, Entresto (Sacubitril and Valsartan Tablets 97mg/103mg), Entresto | Viatris Inc. | Chronic Heart Failure | 04/24 | 08/24 | | |
NCT04299113: Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma |
|
|
| Recruiting | 1 | 38 | US | Vinorelbine, 3'',4''-Didehydro-4''-deoxy-C''-norvincaleukoblastine, 5''-Nor-Anhydrovinblastine, 71486-22-1, Dihydroxydeoxynorvinkaleukoblastine, nor-5''-Anhydrovinblastine, vinorelbine, VINORELBINE, Mocetinostat, 726169-73-9, Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, MG-0103, MGCD0103, MGCD0103, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide | Jonsson Comprehensive Cancer Center, Mirati Therapeutics Inc., Phase One Foundation | Rhabdomyosarcoma | 05/25 | 05/26 | | |
NCT03220477: Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. |
|
|
| Active, not recruiting | 1 | 28 | US | Pembrolizumab, Guadecitabine, Mocetinostat | Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Astex Pharmaceuticals, Inc., Mirati Therapeutics Inc., Stand Up To Cancer, Van Andel Research Institute | Lung Cancer | 07/24 | 07/24 | | |
